Study sheds light on drug’s impact on diabetes progression

A Vanderbilt study of a treatment to delay the development of Type 1 diabetes in individuals at high risk did not meet the study goals of delaying progression from normal glucose tolerance to abnormal glucose tolerance or clinical diagnosis, although the study drug, abatacept, impacted immune response and preserved insulin production during the one-year treatment period.

NIH grant supports TB research network in Brazil

The National Institutes of Health has awarded a five-year, $5 million grant to Vanderbilt University Medical Center for continued support of the Brazil Regional Prospective Observational Research in Tuberculosis network, or RePORT-Brazil.

New high-tech biobank safeguards critical specimens

Study sheds light on the dark side of obesity

Vanderbilt research that promotes the anti-inflammatory pathway in macrophages could also reduce some of the bad side effects of obesity.

VUMC team discovers how bacterial pathogen survives without water

Vanderbilt researchers are studying a bacterial pathogen that can survive on hospital surfaces — without water — for months, an ability that has helped it become a leading cause of hospital-acquired infections.

VU, VUMC research funding surpasses $1 billion

Vanderbilt University and Vanderbilt University Medical Center received more than $1 billion in research funding awarded from external organizations in 2021.